Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717780 | 1.00 | PTGES2 (0.47) | PTGES2CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL27717773 | 0.90 | MAOB (0.44) | PTGES2MAOBHTR2AHTR2CKCNH2 | |
| SCHEMBL5406602 | 0.90 | MAOB (0.44) | PTGES2MAOBHTR2AHTR2CKCNH2 | |
| SCHEMBL27717789 | 0.89 | HTR2A (0.41) | PTGES2MAOBHTR2AHTR2CKCNH2 | |
| SCHEMBL4620011 | 0.89 | HTR2A (0.41) | PTGES2MAOBHTR2AHTR2CKCNH2 | |
| SCHEMBL5409694 | 0.88 | PTGES2 (0.47) | PTGES2CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL28771576 | 0.88 | PTGES2 (0.47) | PTGES2CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL27717775 | 0.87 | PTGES2 (0.48) | PTGES2CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL5414820 | 0.87 | PTGES2 (0.48) | PTGES2CYP1A1CYP1B1MAOBCYP1A2 | |
| SCHEMBL5414240 | 0.87 | CA2 (0.40) | PTGES2HTR2AHTR2CHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | PTGES2 3551/4885CYP1A1 827/4885CYP1B1 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.